Frommel D, Ogunkolade B W, Vouldoukis I, Monjour L
Institut National de la Santé et de la Recherche Médicale U 313, Paris, France.
Infect Immun. 1988 Apr;56(4):843-8. doi: 10.1128/iai.56.4.843-848.1988.
Partially purified antigens, derived from Leishmania infantum or L. major promastigotes and isolated under reducing conditions, were used to immunize BALB/c mice. Three subcutaneous injections of the 64- to 97-kilodalton preparation in conjunction with muramyl dipeptide conferred long-lasting immunity against L. mexicana subsp. mexicana and L. major infection; they led to the development of antibodies neutralizing the infectiousness of promastigotes, induced specific delayed-hypersensitivity reactions, and generated populations of peritoneal macrophages capable of killing amastigotes. Vaccination resulted in no harmful effects, since these antigen neither exacerbated preexisting Leishmania infection nor impeded the formation of antibodies to other antigens administered concomitantly.
源自婴儿利什曼原虫或硕大利什曼原虫前鞭毛体并在还原条件下分离得到的部分纯化抗原，被用于免疫BALB/c小鼠。将64至97千道尔顿的制剂与胞壁酰二肽一起进行三次皮下注射，可赋予对墨西哥利什曼原虫亚种墨西哥利什曼原虫和硕大利什曼原虫感染的持久免疫力；它们导致产生中和前鞭毛体感染性的抗体，诱导特异性迟发型超敏反应，并产生能够杀死无鞭毛体的腹腔巨噬细胞群体。接种疫苗没有产生有害影响，因为这些抗原既没有加剧先前存在的利什曼原虫感染，也没有阻碍对同时给予的其他抗原形成抗体。
